Research and development

Allied Corp Signs Yearly Supply Contract With Veterans for Healing Using the Allied Inside™ Business Model With Colombian Produced Cannabis Flower

Wednesday, November 24, 2021 - 2:52pm

These cigarette packages will be branded with the VFH brand with the Allied Inside mark on the package.

Key Points: 
  • These cigarette packages will be branded with the VFH brand with the Allied Inside mark on the package.
  • The Allied Inside mark signifies that there is Allied Corp produced flower contained.
  • The Allied Inside value proposition enables national brands and companies to brand, market and sell their retail products into their market with the Allied Inside product contained.
  • The Allied product is produced in Colombia and provided as a wholesale product to many international partners to then distribute and sell.

Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand

Wednesday, November 24, 2021 - 1:00pm

Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Key Points: 
  • Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.
  • Canon Medical has been steadily redefining the role of AI in healthcare, starting with its Advanced intelligent Clear-IQ Engine (AiCE).
  • More recently, Canon Medical has transformed the ultrasound space with AI innovations*, that revolutionize clinical workflows.
  • By leveraging the power of AI, Canon Medical has been able to automate these routine tasks to increase clinical productivity and reporting accuracy.

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

Tuesday, November 23, 2021 - 1:00pm

Operating expenses included $2.1 million of non-cash share-based compensation expense in the second quarter of Fiscal 2022, compared to $0.2 million in the second quarter of Fiscal 2021.

Key Points: 
  • Operating expenses included $2.1 million of non-cash share-based compensation expense in the second quarter of Fiscal 2022, compared to $0.2 million in the second quarter of Fiscal 2021.
  • Research & development ("R&D") costs were approximately $1.4 million during the second quarter of Fiscal 2022, compared to approximately $0.8 million during the second quarter of Fiscal 2021.
  • General and administrative ("G&A") expenses were approximately $2.0 million during the second quarter of Fiscal 2022, an increase of approximately $1.6 million from the second quarter of Fiscal 2021.
  • Finally, D&O insurance premiums increased $0.4 million in the second quarter of Fiscal 2022 from the second quarter of Fiscal 2021, due to market rate increases in the cost of coverage.

Harris Affinity Announces Latest Version Release of ADS 10.4.1

Tuesday, November 23, 2021 - 11:00am

WAKEFIELD, Mass., Nov. 23, 2021 /PRNewswire-PRWeb/ --Harris Affinity (Affinity) announces the release of ADS 10.4.1.

Key Points: 
  • WAKEFIELD, Mass., Nov. 23, 2021 /PRNewswire-PRWeb/ --Harris Affinity (Affinity) announces the release of ADS 10.4.1.
  • To learn more about the 10.4.1 release, contact Harris Affinity .
  • Harris Affinity (Affinity) is a worldwide provider of software solutions to help healthcare organizations optimize the financial potential of their facilities and services.
  • Harris Affinity, a wholly-owned subsidiary of N. Harris Computer Corporation, is headquartered in Wakefield, Massachusetts with licensed systems for use at more than 350 hospitals worldwide.

alliantgroup is Honored to Be One of INSIDE Public Accounting's Most Recommended Consultants for 2021

Monday, November 22, 2021 - 8:58pm

HOUSTON, Nov. 22, 2021 /PRNewswire/ --alliantgroup was listed as one of the Most Recommended Consultants for 2021 by INSIDE Public Accounting .

Key Points: 
  • HOUSTON, Nov. 22, 2021 /PRNewswire/ --alliantgroup was listed as one of the Most Recommended Consultants for 2021 by INSIDE Public Accounting .
  • INSIDE Public Accounting (IPA) is an industry leader in practice management resources for the accounting profession.
  • alliantgroup was honored as one of the top 10 most recommended consulting firms.
  • alliantgroup wants to ensure all eligible businesses are aware of the existing federal and state tax credits and incentives available to them.

ACT Genomics and Sanomics Merge to Unleash Hong Kong's Global Potential in Healthcare Technology

Monday, November 22, 2021 - 7:57am

Both ACT Genomics and Sanomics are park companies of Hong Kong Science and Technology Parks Corporation (HKSTP) and located in the Hong Kong Science Park.

Key Points: 
  • Both ACT Genomics and Sanomics are park companies of Hong Kong Science and Technology Parks Corporation (HKSTP) and located in the Hong Kong Science Park.
  • The merger is set to create an integrated oncology diagnostic powerhouse in Asia and unleash the global potential of healthcare technology (healthtech) in Hong Kong, the Greater Bay Area and beyond.
  • Sunny Chai, Chairman of Hong Kong Science & Technology Parks Corporation, Mr. Alfred Sit, Secretary for Innovation and Technology, and Ms. Annie Choi, Permanent Secretary for Innovation and Technology.
  • About ACT Genomics Holdings Co. Ltd.
    ACT Genomics is an innovation-driven cancer solution provider with offices in Hong Kong, Taipei, Singapore, Tokyo, Bangkok and Wales (UK).

Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development

Monday, November 22, 2021 - 7:21pm

Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.

Key Points: 
  • Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.
  • He joins Pharnext from Acorda Therapeutics where he held the position of CMO and Head of Research & Development for the past six years.
  • Prior to this, Dr Blank served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim, Herantis Pharma, and Mersana Therapeutics.
  • Dr. David Horn Solomon, Chief Executive Officer of Pharnext, commented: "I am delighted to welcome Burkhard to the team and look forward to working with him.

DGAP-News: Marinomed Biotech AG Reports Significant Revenue Growth for the First 9 Months 2021

Monday, November 22, 2021 - 7:17pm

Revenue increased by 12.9 % to 5.7 million in the first three quarters of 2021 (9M 2020: 5.1 million).

Key Points: 
  • Revenue increased by 12.9 % to 5.7 million in the first three quarters of 2021 (9M 2020: 5.1 million).
  • Therefore, the loss for the first nine months 2021 was at 6.3 million and fully in line with expectations (9M 2020: 4.8 million).
  • During the first nine months we continued to significantly advance the virus blocking Carragelose products.
  • Marinomed confirms its financial outlook for the fiscal year: the company expects an operating loss for 2021 in line with its business plan and aims to reach profitability in the medium term.

SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update

Monday, November 22, 2021 - 12:00pm

SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) --  SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Nov. 22, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.
  • The business combination, which closed in October 2021, resulted in gross proceeds to SAB of approximately $30 million.
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
  • SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

Monday, November 22, 2021 - 12:30pm

Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.

Key Points: 
  • Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.
  • Were pleased to welcome Richard to our Board, said Dr.Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab.
  • Its an honor to join the Zai Lab Board and to work alongside Samantha and her team in achieving the companys vision of becoming a global biopharmaceutical company, commented Dr. Gaynor.
  • Were excited by the collective expertise the Board will bring to Zai Lab as we strengthen our capabilities and execute our global strategy.